» Articles » PMID: 27478643

Etodolac Containing Topical Niosomal Gel: Formulation Development and Evaluation

Overview
Journal J Drug Deliv
Date 2016 Aug 2
PMID 27478643
Citations 19
Authors
Affiliations
Soon will be listed here.
Abstract

The present study aimed to investigate the delivery potential of Etodolac (ETD) containing topical niosomal gel. Niosomal formulations were prepared by thin film hydration method at various ratios of cholesterol and Span 60 and were evaluated with respect to particle size, shape, entrapment efficiency, and in vitro characteristics. Dicetyl phosphate (DCP) was also added in the niosomal formulation. Mean particle size of niosomal formulation was found to be in the range of 2 μm to 4 μm. Niosomal formulation N2 (1 : 1) ratio of cholesterol and surfactant displayed good entrapment efficiency (96.72%). TEM analyses showed that niosomal formulation was spherical in shape. Niosomal formulation (N2) displayed high percentage of drug release after 24 h (94.91) at (1 : 1) ratio of cholesterol : surfactant. Further selected niosomal formulation was used to formulate topical gel and was characterized with respect to its various parameters such as pH, viscosity, spreadability, ex vivo study, and in vivo potential permeation. Ex vivo study showed that niosomal gel possessed better skin permeation study than the plain topical gel. Further in vivo study revealed good inhibition of inflammation in case of topical niosomal gel than plain gel and niosomal formulation. The present study suggested that topical niosomal gel formulations provide sustained and prolonged delivery of drug.

Citing Articles

Etodolac utility in osteoarthritis: drug delivery challenges, topical nanotherapeutic strategies and potential synergies.

Gaddala P, Choudhary S, Sethi S, Sainaga Jyothi V, Katta C, Bahuguna D Ther Deliv. 2024; 15(12):977-995.

PMID: 39345034 PMC: 11583675. DOI: 10.1080/20415990.2024.2405456.


A QbD-Navigated Approach to the Development and Evaluation of Etodolac-Phospholipid Complex Containing Polymeric Films for Improved Anti-Inflammatory Effect.

Singh J, Kaur S, Chandrasekaran B, Kaur G, Saini B, Kaur R Polymers (Basel). 2024; 16(17).

PMID: 39274149 PMC: 11398249. DOI: 10.3390/polym16172517.


Microporation-Mediated Transdermal Delivery of In Situ Gel Incorporating Etodolac-Loaded PLGA Nanoparticles for Management of Rheumatoid Arthritis.

El Sorogy H, Fayez S, Khalil I, Abdel Jaleel G, Fayez A, Eliwa H Pharmaceutics. 2024; 16(7).

PMID: 39065541 PMC: 11279519. DOI: 10.3390/pharmaceutics16070844.


Olmesartan Medoxomil-Loaded Niosomal Gel for Buccal Delivery: Formulation, Optimization, and Studies.

Palei N, Mohanta B, Rajangam J, Guptha P Turk J Pharm Sci. 2024; 21(3):199-210.

PMID: 38994813 PMC: 11590553. DOI: 10.4274/tjps.galenos.2023.93765.


Niosome as a promising tool for increasing the effectiveness of anti-inflammatory compounds.

Fadaei M, Fadaei M, Kheirieh A, Rahmanian-Devin P, Dabbaghi M, Nazari Tavallaei K EXCLI J. 2024; 23:212-263.

PMID: 38487088 PMC: 10938253. DOI: 10.17179/excli2023-6868.


References
1.
Balakrishnan P, Shanmugam S, Lee W, Lee W, Kim J, Oh D . Formulation and in vitro assessment of minoxidil niosomes for enhanced skin delivery. Int J Pharm. 2009; 377(1-2):1-8. DOI: 10.1016/j.ijpharm.2009.04.020. View

2.
Barakat N . In vitro and in vivo characteristics of a thermogelling rectal delivery system of etodolac. AAPS PharmSciTech. 2009; 10(3):724-31. PMC: 2802138. DOI: 10.1208/s12249-009-9261-y. View

3.
Tas C, Ozkan Y, Okyar A, Savaser A . In vitro and ex vivo permeation studies of etodolac from hydrophilic gels and effect of terpenes as enhancers. Drug Deliv. 2007; 14(7):453-9. DOI: 10.1080/10717540701603746. View

4.
Inoue N, Nogawa M, Ito S, Tajima K, Kume S, Kyoi T . The enantiomers of etodolac, a racemic anti-inflammatory agent, play different roles in efficacy and gastrointestinal safety. Biol Pharm Bull. 2011; 34(5):655-9. DOI: 10.1248/bpb.34.655. View

5.
Shinde U, Kanojiya S . Serratiopeptidase Niosomal Gel with Potential in Topical Delivery. J Pharm (Cairo). 2015; 2014:382959. PMC: 4590824. DOI: 10.1155/2014/382959. View